Effect of MaxEPA in patients with SLE. A double-blind, crossover study

Scand J Rheumatol. 1990;19(2):137-43. doi: 10.3109/03009749009102117.

Abstract

Seventeen patients with moderately active SLE participated in a double-blind, crossover study on the effect of MaxEPA, using olive oil as the control substance. During the first 3 months, 8/17 on Max EPA but only 2/17 on the control substance clinically and serologically improved (p = 0.05), but at 6 months there was no difference. The beneficial effect (if any) of MaxEPA on the disease was short-lived.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Clinical Trials as Topic
  • Docosahexaenoic Acids*
  • Double-Blind Method
  • Drug Combinations
  • Eicosapentaenoic Acid*
  • Fatty Acids, Omega-3 / standards
  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Lupus Erythematosus, Systemic / diet therapy
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / pathology
  • Male
  • Middle Aged

Substances

  • Drug Combinations
  • Fatty Acids, Omega-3
  • Maxepa
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid